Breaking News
4 hours ago
Vaibhavi M.
Praxis Precision Medicines, Inc. reports positive Phase 1/2 EMBRAVE trial results with elsunersen, showing significant seizure reduction in pediatric SCN2A epilepsy patients.
Vaibhavi M.
ImmunityBio, Inc. addresses FDA OPDP concerns on ANKTIVA promotions, removes podcast content, and strengthens compliance measures to ensure accurate communication of approved indications.
Vaibhavi M.
Medicus Pharma Ltd. submits optimized Phase 2 trial design to FDA for Teverelix, targeting prevention of recurrent urinary retention in patients with benign prostatic hyperplasia.
Vaibhavi M.
IDEAYA Biosciences, Inc. doses first patient in Phase 1 trial of IDE574, a dual KAT6/7 inhibitor targeting solid tumors including breast, prostate, colorectal, and lung cancers.
Vaibhavi M.